Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms
Authors:
- Agnes FüttererAFAgnes Fütterer
- Miguel R. CampaneroMCMiguel R. Campanero
- Esther LeonardoELEsther Leonardo
- Luis M. CriadoLCLuis M. Criado
- Juana M. FloresJFJuana M. Flores
- Jesús M. HernándezJesús M. Hernández
- Jesús F. San MiguelJMJesús F. San Miguel
- Carlos Martínez-ACMCarlos Martínez-A
Open Access
- 1 September 2005
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 115 (9) , 2351-2362
Abstract
The myelodysplastic/myeloproliferative diseases (MDS/MPDs) are a heterogeneous group of myeloid neoplasms that share characteristics with chronic myeloproliferative diseases and myelodysplastic syndromes. The broad spectrum of clinical manifestations makes MDS/MPDs extremely difficult to diagnose and treat, with a median survival time of 1–5 years. No single gene defect has been firmly associated with MDS/MPDs, and no animal models have been developed for these diseases. The association of deletions on chromosome 20q with myeloid malignancies suggests the presence of unidentified tumor suppressor genes in this region. Here we show that the recently identified death inducer–obliterator (Dido) gene gives rise to at least 3 polypeptides (Dido1, Dido2, and Dido3) through alternative splicing, and we map the human gene to the long arm of chromosome 20. We found that targeting of murine Dido caused a transplantable disease whose symptoms and signs suggested MDS/MPDs. Furthermore, 100% of human MDS/MPD patients analyzed showed Dido expression abnormalities, which we also found in other myeloid but not lymphoid neoplasms or in healthy donors. Our findings suggest that Dido might be one of the tumor suppressor genes at chromosome 20q and that the Dido-targeted mouse may be a suitable model for studying MDS/MPD diseases and testing new approaches to their diagnosis and treatment.Keywords
This publication has 53 references indexed in Scilit:
- Rap1 and SPA-1 in hematologic malignancyTrends in Molecular Medicine, 2004
- Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorderBlood, 2004
- Atypical Cellular DisordersHematology-American Society Hematology Education Program, 2002
- Myelodysplastic SyndromesHematology-American Society Hematology Education Program, 2002
- Derivation of completely cell culture-derived mice from early-passage embryonic stem cells.Proceedings of the National Academy of Sciences, 1993
- Effects of an Rb mutation in the mouseNature, 1992
- Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogeneCell, 1991
- CHRONIC NEUTROPHILIC LEUKAEMIA ASSOCIATED WITH POLYCYTHEMIA VERA: PATHOGENETIC IMPLICATIONS AND THERAPEUTIC APPROACHBritish Journal of Haematology, 1991
- Neutrophilic myelofibrosis presenting as philadelphia chromosome negative BCR non‐rearranged chronic myeloid leukemiaAmerican Journal of Hematology, 1990
- Mutation and Cancer: Statistical Study of RetinoblastomaProceedings of the National Academy of Sciences, 1971